Navigation Links
Afraxis Enters Collaboration with NIH as Part of Therapeutics for Rare and Neglected Disease Program
Date:9/26/2011

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- Afraxis, a San Diego-based biotechnology company developing drugs to treat rare genetic diseases through the modulation of p21-activated kinase (PAK), announced today that it has been selected to participate in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Disease (TRND) Program. As part of the program, Afraxis will partner with the NIH to pursue the ongoing development of the company's disease-modifying treatments for Fragile X syndrome. Fragile X syndrome is a rare genetic disorder that is the most common inherited form of mental retardation.

"TRND collaborations help companies focusing on rare and neglected diseases overcome one of the biggest obstacles facing all drug development companies: advancing programs through that 'valley of death' between identification of a promising compound, and clinical stage development when a program becomes more attractive to a big pharma partner," said Jay Lichter, Ph.D., president and CEO of Afraxis. "This is a tremendous opportunity for Afraxis as the NIH is providing access to state-of-the-art laboratory facilities, the expertise of collaborating NIH scientists, and the financial resources to continue our research and development efforts through the initiation of human clinical trials."

Afraxis is developing disease-modifying treatments for Fragile X syndrome and other central nervous system disorders based on a leadership position in the understanding of PAK biology. Fragile X symptoms can range from learning disabilities to more severe cognitive or intellectual disabilities, such as mental retardation. Fragile X is the most common known cause of autism or "autistic-like" behaviors. The disease is caused by a mutation in the FMR gene on t
'/>"/>

SOURCE Afraxis
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
5. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
6. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
9. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
10. AcroMetrix Renews Contract With Group Services for Americas Blood Centers
11. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Colo. , May 24, 2013  Heska Corporation (NASDAQ: ... diagnostic and specialty products, announced today that Dr. ... officer, and Jason Napolitano , executive vice ... Annual Marcum MicroCap Conference, which is being held May 30, ... the Grand Hyatt Hotel. The Company,s presentation ...
(Date:5/24/2013)... In accordance with Rule 17.1 and Rule 2.9 of the ... Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today announced ... Background On 2 May 2013, Echo ... entire of the issued and to be issued share capital ... On 20 May 2013, Royalty Pharma announced the terms ...
(Date:5/24/2013)... CITY, England and BOSTON ... leading GPCR drug discovery and development company, is pleased to announce ... as a Consultant to augment the Company,s business development capabilities in ... Mr Usui has more than 15 years of experience in business ... roles at Perlegen Sciences, Inc., Roche Pharma ( Japan ...
Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
... Study Comparing Leading Hepatitis C Therapies Provides ... Insights to Help Guide Clinical Practice, MILAN, Italy, ... first large, randomized, clinical study comparing the,leading therapies for ... Meeting of the European Association for the Study of ...
... of treatment with R7128 1500mg BID with Pegasys(R) plus Copegus(R) -, - Safety and ... ... presentation available on Pharmasset website -, - Conference call scheduled for Friday, April 25, 2008 at ... and 7:00 PM CEST (Milan) -, ...
Cached Medicine Technology:Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 2Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 3Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 4Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 5Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 6
(Date:5/25/2013)... The report “Global Food Encapsulation ... Applications, Ingredients, Shell Materials, Packaging, & Geography: Trends ... encapsulation market with analysis and forecasting of the ... the driving and restraining factors for the global ... and challenges. The market is segmented and revenue ...
(Date:5/25/2013)... Providing patients with their best weight loss is ... management professionals. But, aside from educating patients on how to ... hCG diets also provide patients, who have gained weight ... more control over their lives by achieving their best weight ... factors of weight gain derived from earlier abuse, Diet Doc's ...
(Date:5/25/2013)... York (PRWEB) May 25, 2013 Pradaxa ... suffered serious, life-threatening episodes of internal bleeding while using the ... in U.S. District Court, Southern District of Illinois, Bernstein Liebhard ... website, 818 Pradaxa side effect claims had been ... That’s up from 705 claims reported by the Court on ...
(Date:5/25/2013)... 2013 On May 25, Voices Against ... and advocacy, comments on a new study by the ... cold atmospheric plasma into brain cancer treatment may help ... a Science Daily article, physicists from the ... physicians demonstrated the “synergistic effect of cold atmospheric plasma ...
(Date:5/25/2013)... May 25, 2013 Dr. Farooq Ashraf, ... clinic in Dubai, has announced his practice’s adoption of ... the only FDA-cleared femtosecond laser proven with more than ... and precision of LASIK. , “We are happy to ... Femtosecond Laser at our Dubai LASIK practice,” Ashraf said ...
Breaking Medicine News(10 mins):Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2
... at about 15 months of age to prevent heart disease ... bmj.com today. , High cholesterol which runs ... two in every 1000 people and causes very high levels ... blood. It carries a high risk of death from coronary ...
... expand options, reduce costs for ECC training, ... Heart,Association research has supported education and training programs ... lives each year.,Now, healthcare providers have more ways ... as the organization introduces a,significantly expanded eLearning program. ...
... Hospital Group to Automate and Connect 165 ... Physicians Across 36 Medical Groups, ... the leading provider of clinical software, connectivity and,information solutions that ... Health System (WPAHS) has selected,Allscripts as its Electronic Health Record ...
... to Make a Blood Donation to Honor Blood ... Collectors and Support Their Communities, LAKE ... of September 16-22, 2007, blood collection centers across the,United States ... and Fenwal, Inc. This celebratory week recognizes the important,service blood ...
... requires lifelong dependence on insulin injections, researchers say , ... insulin-linked gene can cause permanent neonatal diabetes, say American ... mutations in 21 people from 16 families. , Permanent ... affects infants and leads to lifelong dependence on insulin ...
... Saturday,September 15 will mark the first national "Short ... advocacy group, will be holding special,events in several ... City and,Washington, DC, musicians with psoriasis will headline ... have a,cookout; and across the country, people with ...
Cached Medicine News:Health News:Experts propose cholesterol tests at 15 months of age 2Health News:American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC) 2Health News:American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC) 3Health News:American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC) 4Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 2Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 3Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 4Health News:AABB and Fenwal Sponsor Third Annual Blood Collectors Week 2Health News:AABB and Fenwal Sponsor Third Annual Blood Collectors Week 3Health News:Gene Mutations May Cause Rare Neonatal Diabetes 2Health News:Psoriasis Cure Now Rolls Out First National 'Short Sleeve Day' Saturday 2
... clip appliers in 10mm and 5mm sizes. ... precise clip placement., ,The LIGACLIP ERCA ... sterile, single patient use instrument designed to ... Surgical Trocars. The instrument delivers 20 titanium ...
The C-Reactive Protein (CRP) assay is used for the quantitative analysis of C-reactive protein in human serum and plasma. Kit is for use with the Abbot Laboratories Aeroset, ARCHITECT c8000 or ARCHI...
... laboratories to work more efficiently has ... for innovative solutions. With the COBAS ... on-board measurement technologies, robotic handling of ... This supports the very broad menu ...
... are titanium anchors that come in several ... are simple to use and convenient for ... sizes and styles are available: 3.0mm Single ... Sutures, 5.0mm Double Eyelet 2 Sutures, and ...
Medicine Products: